Blood therapeutics company Grifols (NASDAQ:GRFS) will hold a grand opening for a new facility in Clayton expected to employ 200 workers when it becomes fully operational next year.
Grifols, headquartered in Barcelona, Spain, uses components of blood to make biologically-based therapies to treat rare and chronic diseases. On Tuesday, Grifols will mark the opening of its new North Fractionation Facility in Clayton. Fractionation is the process in which the plasma proteins are separated out from the blood in order to produce the therapeutics that Grifols makes. Grifols is already the largest private employer in Johnston County, employing 1,650. The company has 2,300 employees statewide.
Grifols expanded its reach into North America with its $4 billion acquisition of Research Triangle Park-based Talecris Biotherapeutics in 2011. Grifols took over Talecris’ sites, including a manufacturing plant in Clayton. But in order to win Federal Trade Commission’s blessing of the acquisition, Grifols and Talecris agreed that Talecris would divest a fractionation facility in Melville, New York. Grifols says that its new Clayton fractionation facility will almost double the company’s plasma production capacity.
A number of government and business dignitaries are scheduled to attend Tuesday’s grand opening including Grifols President and CEO Victor Grifols; Gov. Pat McCrory; Clayton Mayor Jody McLeod; and Spanish Ambassoador to the United States Ramon Gil-Casares.